This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnArchive
23 July 2026
The framing here is agent endurance, not just benchmark scores. If Anthropic is explicitly targeting long-running agent reliability, that's the bottleneck most builders have hit trying to move past demo-stage agents into production. Worth re-testing any agent workflow you shelved due to context drift or tool-call failures over long sessions.
OpenAI moving into consumer health data is a serious regulatory and trust bet, not a minor feature ship. Expect scrutiny on HIPAA-adjacent handling and data use, and expect competitors to follow fast since consumer health is one of the few remaining high-value, low-competition ChatGPT verticals. Builders in health tech should watch what data access model OpenAI settles on, it will shape the API surface others build against.
The interesting claim is efficiency: a much smaller MoE reportedly outperforming a model an order of magnitude larger, which if true says more about training methodology than raw compute spend. For builders and investors, this is a data point on whether the 'just scale bigger' era is giving way to a 'scale smarter' era, worth reading the interview for the specifics rather than taking the headline claim at face value.
Mollick's periodic tool guides are useful precisely because they track the churn in which model wins which task, and that churn is the real story of this market right now. Worth a skim for the specific task-to-tool mapping rather than any grand thesis, since the value decays fast as new releases land.
Another entrant in the price-performance race among Chinese and neolab open models, worth tracking for teams optimizing inference cost. The claim needs independent benchmark verification before switching production traffic, but the pattern of new labs undercutting DeepSeek on cost is now a recurring monthly event.
Coming soon. In the meantime, the Tuesday Brief is free.
Get the free brief